In lung cancer PD-1/PD-L1 inhibitors were shown to be superior over chemotherapy (61), recently a durable effect of combination therapy with anti-PD-1 nivolumab and anti-CTLA-4 ipilimumab in advanced cancer was shown (62). Here, CD274 is linked to cancer.